Coegin Pharma has a solid patent portfolio with 21 patent families including substance patents, user patents, combination patents and formulation patents. The patent families in the table below have been filed in the United States, Europe, Canada, Japan, Australia and also in other areas such as China, Hong Kong, Korea, India, Israel, New Zealand and Norway.
1 FOL-005 Hair growth stimulation PCT/GB2012/051955
2 Peptides for treatment of diabetes PCT/EP2018/061547
3 Peptides fragments for treatment of diabetes PCT/EP2019/080563
4 Topical formulation of FOL-005 PCT/EP2020/061453
5 Peptides for use in skin and hair pigmentation PCT/EP2021/080032
6 FOL peptides for wound healing Priority application
7 FOL peptides for vascularization Priority application
03 AVX001/AVX002 type compounds for the treatment of glomerulonephritis PCT/EP2010/003384
04 Oxothiazole compounds and their use for the treatment of certain chronic inflammatory conditions PCT/EP2010/064687
06 Oxothiazole compounds and their use in the treatment of chronic inflammatory disorders and proliferative disorders such as cancer PCT/EP2014/051655
10 AVX001 type ketones for the treatment of skin cancer PCT/EP2015/061534
12a AVX001 and AVX002 in combination with BEZ235 PCT/EP2017/056022
12f AVX235 and AVX420 in combination with BEZ235 PCT/EP2017/056016
16a Formulation comprising AVX001 type ketones and silicone PCT/EP2017/073951
19b AVX420 type compounds in combination with PI3K inhibitors PCT/EP2020/063717
21 AVX001 type ketones for the treatment of fibrotic diseases PCT/EP2018/066028
23 Oxothiazole compounds for the treatment of fibrotic diseases PCT/EP2019/060544
25 AVX001/AVX002 type compounds for use in the prevention of metastasis in cancer PCT/EP2020/071168
26 AVX001/AVX002 type compounds for use in the treatment of actinic keratosis or squamous cell carcinoma PCT/EP2021/087848
27 2-Oxothiazole compositions for treatment for T-cell acute lymphoblastic leukemia Priority application